Stock VITR VITROLIFE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vitrolife AB

Equities

VITR

SE0011205202

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:32 2024-04-26 am EDT 		5-day change 1st Jan Change
163.3 SEK +3.62% Intraday chart for Vitrolife AB -0.24% -16.13%
Apr. 25 Vitrolife AB Approves Dividend for the Financial Year 2023 CI
Apr. 18 Nordic Stocks Closed Down Thursday; Arjo Series B Fell Furthest DJ

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 21,439 23,425 75,821 25,210 26,361 22,110 - -
Enterprise Value (EV) 1 20,825 22,514 77,673 26,857 27,589 22,710 22,007 21,327
P/E ratio 55.9 x 81.7 x 189 x 64 x -6.85 x 41.7 x 32.7 x 30.3 x
Yield 0.53% 0.37% 0.14% 0.46% 0.51% 0.83% 0.85% 1.26%
Capitalization / Revenue 14.5 x 18.8 x 45.1 x 7.8 x 7.51 x 6.14 x 5.56 x 5.25 x
EV / Revenue 14.1 x 18.1 x 46.2 x 8.3 x 7.86 x 6.31 x 5.53 x 5.06 x
EV / EBITDA 35.5 x 49.6 x 120 x 25.6 x 24.3 x 19.3 x 16.4 x 14.8 x
EV / FCF 52.8 x 66.9 x 246 x 54.6 x 42.8 x 28.9 x 25.2 x 22 x
FCF Yield 1.89% 1.49% 0.41% 1.83% 2.33% 3.46% 3.97% 4.55%
Price to Book 11.9 x 11.6 x 4.95 x 1.51 x 2.07 x 1.68 x 1.64 x 1.53 x
Nbr of stocks (in thousands) 108,551 108,551 135,395 135,395 135,395 135,395 - -
Reference price 2 197.5 215.8 560.0 186.2 194.7 163.3 163.3 163.3
Announcement Date 2/6/20 2/10/21 2/16/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,480 1,246 1,681 3,234 3,512 3,601 3,977 4,215
EBITDA 1 587 454 645 1,050 1,136 1,179 1,338 1,440
EBIT 1 487.9 370 536.4 654 -3,589 757.3 918.2 1,008
Operating Margin 32.97% 29.7% 31.91% 20.22% -102.19% 21.03% 23.09% 23.91%
Earnings before Tax (EBT) 1 492.7 366.2 460 537 -3,712 683.7 874.6 952.5
Net income 1 382.8 288 341 394 -3,851 529.9 676.6 731
Net margin 25.86% 23.11% 20.28% 12.18% -109.65% 14.71% 17.01% 17.34%
EPS 2 3.530 2.640 2.970 2.910 -28.44 3.913 4.993 5.395
Free Cash Flow 1 394.2 336.4 315.8 492 644 786.7 874.3 970
FCF margin 26.64% 27% 18.78% 15.21% 18.34% 21.85% 21.99% 23.01%
FCF Conversion (EBITDA) 67.16% 74.09% 48.96% 46.86% 56.69% 66.71% 65.33% 67.38%
FCF Conversion (Net income) 102.99% 116.79% 92.61% 124.87% - 148.45% 129.23% 132.69%
Dividend per Share 2 1.050 0.8000 0.8000 0.8500 1.000 1.350 1.383 2.050
Announcement Date 2/6/20 2/10/21 2/16/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 514 752 829 798 855 854 905 848 904 841 905.7 892.1 962.5 903 963
EBITDA 1 164 228 273 276 273 262 293 287 294 272 298 291.4 317.5 307 330
EBIT 1 118.6 133 175 177 168 159 188 179 -4,115 - 192.3 185.8 211.8 200 223
Operating Margin 23.07% 17.69% 21.11% 22.18% 19.65% 18.62% 20.77% 21.11% -455.2% - 21.24% 20.82% 22.01% 22.15% 23.16%
Earnings before Tax (EBT) 1 61.31 113 169 149 106 130 135 152 -4,130 - 169.2 168.9 202 190 213
Net income 1 32.62 82 130 108 74 100 106 122 -4,179 - 129.9 129.7 154.7 147 165
Net margin 6.35% 10.9% 15.68% 13.53% 8.65% 11.71% 11.71% 14.39% -462.28% - 14.34% 14.54% 16.07% 16.28% 17.13%
EPS 0.2600 0.6000 0.9600 0.8000 0.5500 - 0.7800 0.9000 -30.86 - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/16/22 4/22/22 7/15/22 10/27/22 2/2/23 4/21/23 7/14/23 10/27/23 2/2/24 4/18/24 - - - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 1,852 1,647 1,228 600 - -
Net Cash position 1 614 911 - - - - 103 783
Leverage (Debt/EBITDA) - - 2.872 x 1.569 x 1.081 x 0.5089 x - -
Free Cash Flow 1 394 336 316 492 644 787 874 970
ROE (net income / shareholders' equity) 22.8% 15.1% 3.93% 2.46% 3.05% 4.07% 4.8% 5.67%
ROA (Net income/ Total Assets) 20% 12.9% 3.14% 1.97% 2.43% 3.2% 3.9% 4.6%
Assets 1 1,919 2,231 10,867 19,990 -158,158 16,559 17,349 15,891
Book Value Per Share 2 16.50 18.50 113.0 124.0 94.20 97.20 99.70 107.0
Cash Flow per Share 3.800 3.280 - - - - - -
Capex 1 87.1 20.1 68.5 83 113 76.5 111 89
Capex / Sales 5.89% 1.61% 4.08% 2.57% 3.22% 2.12% 2.79% 2.11%
Announcement Date 2/6/20 2/10/21 2/16/22 2/2/23 2/2/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Vitrolife AB

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
163.3 SEK
Average target price
231.7 SEK
Spread / Average Target
+41.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-5.02% 1.64B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. VITR Stock
  4. Financials Vitrolife AB